Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF)

Exclusion Criteria

• •Other invasive malignancy within 5 years
• •More than 3 different metastatic sites
• •\>50% liver involvement by metastasis
• •Newly diagnosed untreated Stage IIIB breast cancer
• •Prior chemotherapy for metastatic disease
• •Clinically significant cardiovascular disease
• •History or evidence of CNS disease
• •Major surgery within 28 days prior to day 0
• •Current or recent use of parenteral anticoagulants
• •WBC \< 3,000/uL
• •Platelet count \< 75,000/uL
• •Hemoglobin \< 9.0 g/dL
• •Total Bilirubin \> 2.0 mg/dL
• •AST or ALT \> 5 time upper limit of normal for subjects with documented liver metastases; \> 2.5 times upper limit of normal for subjects without evidence of liver metastases
• •Proteinuria (\> 1g protein/24 hours at baseline)
• •Prior therapy with Herceptin or rhuMAb VEGF (bevacizumab)